M.D., O.D. · Neonatologist & Optometrist
Associate Professor of Pediatrics and Ophthalmology at the University of Rochester. Bench-to-bedside researcher in retinopathy of prematurity, neonatologist, global health advocate, and Medical Mission Director of the Mezu International Foundation.
From Nigeria to the forefront of neonatal retinal research — three decades in six chapters.
Expand each chapter to reveal all milestones
Dual-trained as a neonatologist and licensed optometrist — a rare combination that directly informs her bench-to-bedside research on retinopathy of prematurity, the leading cause of preventable blindness in premature infants.
Bridges laboratory discovery and clinical application — from developing VEGF-A165a and calcitriol therapies, to pioneering Bevacizumab-loaded PLGA nanoparticles for sustained intravitreal drug delivery in premature infants.
Medical Mission Director of the Mezu International Foundation — leading 21+ years of annual free medical missions to Imo State, Nigeria, serving 1,500+ patients per year and mentoring the next generation of global health researchers.
Committed to addressing systemic racism and unconscious bias in medical workplaces. Author of a landmark JAHA commentary calling for servant leadership in medicine. Advocates for reducing global health disparities through education, research, and humanitarian service.
Contributor to four major medical textbooks spanning public health, clinical leadership, neonatal immunology, and nutrition. Identifies as Author and Poet — bringing a humanistic dimension to scientific communication and medical education.
Beyond the bench, Dr. Mezu-Ndubuisi builds software tools that solve real problems for researchers — from open-source retinal analysis to a full SaaS platform for vivarium management.
Retinal Vessel Quantification Tool
A MATLAB program for quantitative analysis of retinal vascular features in fluorescein angiography images. Enables precise, reproducible measurement of vessel density, avascular area, and neovascular tuft formation in the OIR model. Freely available to the global research community.
Optom Vis Sci. 2016 Oct; 93(10):1268–1279
quantbv.com ↗Research Colony Management Platform
A purpose-built SaaS platform that replaces error-prone Excel workflows for vivarium colony management. Automatic P-day calculations (P0–P103), smart wean-check alerts, team collaboration with role-based access, AI-powered colony insights, and IACUC-compliant audit trails. Supports mouse, rat, rabbit, guinea pig, bird, sheep, and lamb colonies.
From $14.99/mo · 14-day free trial
colotra.app ↗Recognition spanning three decades — from Nigeria to the National Institutes of Health.
Lab students presented one oral and three poster abstracts at the American Public Health Association annual conference — November 2–4, 2025.
Published in Pediatric Research (Nature) — the first demonstration that intravitreal Bevacizumab-loaded PLGA nanoparticles can ameliorate retinal vasculopathy in a mouse model of ROP.
Prakriti presented on visual impairment in Southeast Nigeria at the Global Ophthalmology Summit (Chicago). OlaRose Ndubuisi presented on scoliosis screening at the Pediatric Academic Societies meeting (Honolulu).
Kamsi Oparaugo received a $5,000 Schwartz Discover Grant for global health research conducted during the Mezu International Foundation medical mission to Imo State, Nigeria.
Recognized among Rochester's top physicians for excellence in neonatal care and dedication to improving outcomes for premature infants.
"Unmasking Systemic Racism and Unconscious Bias in Medical Workplaces: A Call to Servant Leadership" — published in the Journal of the American Heart Association.
Received a $50,000 research grant from the UnityPoint Health-Meriter Foundation for neonatology research, following an earlier $20,000 grant from the same foundation in 2016.
Five-year K08 award (5K08EY032203) from the National Eye Institute. Funds research on the mechanism of intravitreal VEGF-A165a and topical calcitriol for the treatment of ROP.
Dr. Mezu-Ndubuisi brings a humanistic dimension to medicine and science. As an author and poet, she understands that the most powerful scientific communication speaks to the human experience — not just the data.
Open to collaborations, media inquiries, speaking engagements, and prospective students or postdocs interested in joining the lab.